...
机译:曲妥珠单抗治疗转移性乳腺癌患者的人群研究中的HER2检测
Frances P. O'Malley, MD, Tom Thomson, MD, Jim Julian, MSc, Cherry Have, MSc, Roxanne Crosby, BSc, Karen Gelmon, MD, Irene Andrulis, PhD, Tim Whelan, MDAccepted for publication August 8, 2007.From the Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario (Dr O'Malley and Ms Have), the Departments of Pathology (Dr Thomson) and Medical Oncology (Dr Gelmon), British Columbia Cancer Agency, Vancouver, the Department of Clinical Epidemiology and Biostatistics (Mr Julian), the Program in Evidence Based Care (Ms Crosby), and the Department of Medicine, Division of Radiation Oncology (Dr Whelan), McMaster University, Hamilton, Ontario, and the Samuel Lunenfeld Research Institute and Department of Pathology and Laboratory Medicine, Mount Sinai Hospital and University of Toronto, Toronto, Ontario (Dr Andrulis).The authors have no relevant financial interest in the products or companies described in this article.Reprints: Frances P. O'Malley, MD, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave, Toronto, Ontario, Canada M5G 1X5 (e-mail: fomalley@mtsinai.on.ca).,;
机译:在Her2阳性局部晚期/转移性乳腺癌患者中,Hertuzumab患者的随机开放标签,腹部疗法试验,曲妥珠单抗和化疗:日本乳腺癌研究组-M05珍贵研究
机译:二线抗HER2治疗在先前接受曲妥珠单抗治疗的HER2阳性转移性乳腺癌患者中的有效性:一项现实世界研究
机译:T-PAS扩大获取研究结果显示,曲妥珠单抗Emtansine(T-DM1)用于先前接受过化疗和2种或更多种HER2靶向药物治疗的HER2阳性转移性乳腺癌患者
机译:HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关:回顾性和多中心研究
机译:Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
机译:二线抗HER2治疗在先前接受曲妥珠单抗治疗的HER2阳性转移性乳腺癌患者中的有效性:一项现实世界研究
机译:在Her2-阳性局部晚期/转移性乳腺癌患者中,Hertuzumab患者的随机开放标签,腹部疗法试验,先前用Pertuzumab,Trastuzumab和化疗治疗:日本乳腺癌研究组-M05珍贵研究